REVIEW article
Front. Aging Neurosci.
Sec. Alzheimer's Disease and Related Dementias
The locus coeruleus, a blue spot for early diagnosis and prognosis of Alzheimer's disease
Provisionally accepted
- 1Tulane Cancer Center, School of Medicine, Tulane University, New Orleans, Louisiana, United States
- 2School of Medicine, University of California, Davis, Sacramento, California, United States
- 3Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Alborz, Iran
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Intact functioning of the locus coeruleus-noradrenergic (LC-NA) system is pivotal in the control of numerous central processes, and damage to these systems leads to a wide range of nervous system disorders. The LC, as the main source of noradrenaline (NA) in the mammalian brain, was the first central nervous system (CNS) modulatory structure to be anatomically and biochemically characterized. LC-NA release exerts both excitatory and inhibitory effects on target areas. Over the past few decades, LC damage has been causatively identified as a common factor in CNS diseases, notably neurodegenerative diseases. Moreover, LC damage is the likely manifestation of common pathophysiological processes, thus elevating the LC as a diagnostic and therapeutic target, especially in Parkinson's and Alzheimer's diseases (PD & AD). This review also addresses why LC neurons, compared to other areas in particular, are highly vulnerable and sensitive to damage—such as specific anatomical features, tau phosphorylation, and high neuronal energy requirements—will be described in this review article. Finally, we explore whether these known LC vulnerabilities might be leveraged towards improved early diagnostic and prognostic biomarkers for AD.
Keywords: Locus Coeruleus, Vulnerability, neurodegenerative disease, noradrenaline, biomarker, Alzheimer's disease
Received: 20 May 2025; Accepted: 12 Nov 2025.
Copyright: © 2025 Farahani, Anaclet, Azizi and Gompf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Heinrich S Gompf, heinrich.gompf@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.